newsfilter
← Latest News
Business Wire·

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral